Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)



Status:Active, not recruiting
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:9/7/2017
Start Date:September 2010
End Date:October 30, 2017

Use our guide to learn which trials are right for you!

A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia

The purpose of this study is to determine the efficacy of ponatinib in patients with chronic
myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or
with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or
intolerant to either dasatinib or nilotinib, or have the T315I mutation.

The preliminary analysis of the phase 1 clinical trial revealed evidence of clinical
antitumor activity in patients with resistance to approved second-generation tyrosine kinase
inhibitors (TKI), dasatinib and nilotinib, including patients with the T315I mutation of the
BCR-ABL gene (BCR-ABL). This Phase 1 study, taken together with the strong preclinical data
that characterize ponatinib, provides the rationale for moving to a pivotal phase 2 trial of
this agent in a population of patients with chronic myeloid leukemia (CML) and Ph+ Acute
Lymphoblastic Leukemia (ALL) who are resistant or intolerant to prior TKI therapy and in
those patients with the T315I mutation.

PACE is a multi-center, international, phase 2, uncontrolled, open-label trial of oral
ponatinib in patients with Philadelphia chromosome-positive (Ph+) disease.

Inclusion Criteria:

- Patients must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL

- Previously treated with and developed resistance or intolerance to dasatinib or
nilotinib OR developed the T3151 mutation after any tyrosine kinase inhibitor (TKI)
therapy

- ≥18 years old

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Minimum life expectancy of ≥3 months

- Adequate kidney function

- Adequate liver function

- Normal pancreatic function

- Normal QT Fridericia-corrected interval (QTcF) ≤450 ms for males and ≤470 ms for
females

- Negative pregnancy test (if woman of childbearing potential)

- Agree to use effective form of contraception (as applicable)

- Ability to comply with study procedures, in the Investigator's opinion

Exclusion Criteria:

- Received prior TKI treatment within 7 days prior to receiving the first dose of
ponatinib, or have not recovered from adverse events (except alopecia) due to agents
previously administered.

- Received other therapies as follows:

1. For CML chronic phase (CP) and accelerated phase (AP) patients, received
hydroxyurea or anagrelide within 24 hours prior to receiving the first dose of
ponatinib; interferon, cytarabine, or immunotherapy within 14 days prior to first
dose of ponatinib; or any other cytotoxic chemotherapy, radiotherapy, or
investigational therapy within 28 days prior to receiving the first dose of
ponatinib.

2. For CML blast phase (BP) patients, received chemotherapy within 14 days prior to
the first dose of ponatinib.

3. For Ph+ ALL patients, received corticosteroids within 24 hours before the first
dose of ponatinib; or vincristine within 7 days prior to the first dose of
ponatinib; or received other chemotherapy within 14 days prior to the first dose
of ponatinib.

- Underwent stem cell transplant <60 days prior to receiving first dose of ponatinib

- Evidence of on-going graft versus-host disease (GVHD), or GVHD requiring
immunosuppressive therapy

- Taking medications that are known to be associated with Torsades de Pointes

- Require concurrent treatment with immunosuppressive agents (other than corticosteroids
prescribed for a short course of therapy)

- Previously treated with ponatinib

- CML CP patients are excluded if they are in Complete cytogenetic response (CCyR)

- Patients with CML AP, CML BP, or Ph+ ALL are excluded if they are in Major Hematologic
Response (MaHR).

- Have active Central Nervous System (CNS) disease

- Have significant or active cardiovascular disease

- Have a significant bleeding disorder unrelated to CML or Ph+ALL

- Have a history of pancreatitis or alcohol abuse

- Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)

- Have malabsorption syndrome or other gastrointestinal illness that could affect
absorption of ponatinib

- Diagnosed with another primary malignancy in the past 3 years

- Pregnant or lactating

- Underwent major surgery within 14 days prior to first dose of ponatinib

- Have ongoing or active infection

- Suffer from any other condition or illness that would compromise safety or interfere
with evaluation of the drug
We found this trial at
18
sites
303 E Chicago Ave
Chicago, Illinois 60611
(312) 503-8194
Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, founded in 1859,...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lincoln, Nebraska 68506
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Los Angeles, California 90024
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Portland, Oregon 97227
?
mi
from
Portland, OR
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
2000 Circle of Hope Dr
Salt Lake City, Utah 84112
(801) 585-0303
Huntsman Cancer Institute at University of Utah Huntsman Cancer Institute (HCI) is part of the...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
St. Leonards, New South Wales 2065
?
mi
from
St. Leonards,
Click here to add this to my saved trials